Laekna Pharmaceutical Ningbo Co. Ltd. has synthesized phosphatidylinositol 3-kinase α (PI3Kα) and its mutant (H1047R) inhibitors reported to be useful for the treatment of breast cancer.

OnKure Therapeutics provided an update on its ongoing clinical trials and financial results for 2024, highlighting significant progress in their PI3Kα inhibitor programs. The PIKture-01 trial is ...

For a while, special purpose acquisition companies were biotech’s hot ticket to the public markets. | For a while, special ...

PI3Kα mutations are prevalent in patients with breast, colorectal, lung, endometrial, and numerous other cancers. However, ...

SNV4818 is a potentially best-in-class pan-mutant-selective PI3Kα inhibitor that may effectively cover kinase (H), helical domain (E), and other PI3Kα mutations clinically. This marks the second ...

Its flagship PI3Kα inhibitor RLY-2608 and recently out-licensed FGFR2 inhibitor RLY-4008 have received much attention, but the wider implications of its pipeline strategy have been overlooked.

The firm highlighted OnKure Therapeutics as a clinical-stage company focused on precision oncology, specifically developing targeted PI3Kα inhibitors for the treatment of breast cancer and other ...

"We are thrilled to present the first clinical data for our lead program, OKI-219, which is the only highly selective PI3Kα H1047R inhibitor molecule in the clinic,” said Nicholas Saccomano, Ph.D., ...

CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining ...

PI3Kα mutations are prevalent in patients with breast, colorectal, lung, endometrial, and numerous other cancers. However, the first-generation drugs targeting PI3Kα inhibit the wild-type and ...